UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050399
Receipt number R000057387
Scientific Title Effect on blood flow by wearing home-use far-infrared blood circulation-promoting clothing : a randomized, double-blind, placebo-controlled, cross-over trial.
Date of disclosure of the study information 2023/02/21
Last modified on 2023/03/29 10:43:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect on blood flow by wearing home-use far-infrared blood circulation-promoting clothing

Acronym

Y_S+B study

Scientific Title

Effect on blood flow by wearing home-use far-infrared blood circulation-promoting clothing : a randomized, double-blind, placebo-controlled, cross-over trial.

Scientific Title:Acronym

Effect on blood flow by wearing home-use far-infrared blood circulation-promoting clothing

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare and evaluate the effect on blood flow when wearing clothes intended to improve symptoms such as fatigue and muscle stiffness by promoting blood circulation of far infrared rays.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

blood flow

Key secondary outcomes

Sublingual body temperature, body surface temperature, blood pressure, VAS


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Wearing test article A

Interventions/Control_2

Wearing test article B

Interventions/Control_3

Wearing placebo

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

59 years-old >=

Gender

Male and Female

Key inclusion criteria

Healthy Japanese men and women

Key exclusion criteria

1. Pregnant women, those who are breastfeeding, or those who may become pregnant
2. Subjects taking drugs that affect hemodynamics
3. Subjects who are receiving treatment, medication, or lifestyle guidance from a doctor
4. Subjects who work night shifts or day and night shifts
5. Subjects with heart disease or hypertension
6. Subjects taking supplements that affect blood flow and coldness
7. Subjects undergoing hormone replacement therapy
8. Subjects whose test date is within 2 weeks from the most recent vaccination
9. Subjects with serious cerebrovascular disease, heart disease, liver disease, renal disease, digestive system disease, infectious disease requiring notification, etc.
10. Subjects who have participated in, or plan to participate in, other clinical studies that are affected by this study within one month prior to obtaining informed consent
11. Other subjects judged inappropriate by the principal investigator

Target sample size

16


Research contact person

Name of lead principal investigator

1st name Takeshi
Middle name
Last name Kaneko

Organization

Japan Clinical Trial Association

Division name

N.A.

Zip code

1600022

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

TEL

0364574666

Email

info@yakujihou.org


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Kaneko

Organization

Japan Clinical Trial Association

Division name

N.A.

Zip code

1600022

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

TEL

0364574666

Homepage URL


Email

info@yakujihou.org


Sponsor or person

Institute

Japan Clinical Trial Association

Institute

Department

Personal name



Funding Source

Organization

YAMAMOTO CORPORATION

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Pharmaceutical Law Wisdoms

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

Tel

0364574911

Email

master@yakujihou.net


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 02 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

16

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 01 Month 05 Day

Date of IRB

2023 Year 02 Month 02 Day

Anticipated trial start date

2023 Year 02 Month 20 Day

Last follow-up date

2023 Year 02 Month 21 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 02 Month 21 Day

Last modified on

2023 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057387


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name